[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350378-105":59,"doc-detail-350378-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dynamic-changes-in-homologous-recombination-status-before-and-after-chemotherapy-in-advanced-ovarian-fallopian-tube-and-primary-peritoneal-cancers","Dynamic changes in homologous recombination status before and after chemotherapy in advanced ovarian, fallopian tube, and primary peritoneal cancers","","Homologous recombination (HR) status is critical for managing advanced ovarian cancers, especially for selecting PARP inhibitor therapy. This study assessed how neoadjuvant chemotherapy (NAC) affects HR status by comparing paired tumor samples obtained before and after NAC in patients undergoing interval debulking surgery (IDS). Genomic instability scores (GIS) and tumor BRCA (tBRCA) mutations were measured using a Myriad myChoice assay.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dynamic-changes-in-homologous-recombination-status-before-and-after-chemotherapy-in-advanced-ovarian-fallopian-tube-and-primary-peritoneal-cancers/350378/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dynamic-changes-in-homologous-recombination-status-before-and-after-chemotherapy-in-advanced-ovarian-fallopian-tube-and-primary-peritoneal-cancers/350378.png","ImageObject",300,407,{"name":92,"@type":93},"Stanford","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary objective of the study?","Question",{"text":112,"@type":113},"To evaluate the impact of neoadjuvant chemotherapy (NAC) on homologous recombination (HR) status using paired tumor samples collected before and after NAC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were HR status and genomic changes measured?",{"text":117,"@type":113},"The study used genomic instability scores (GIS) and tumor BRCA (tBRCA) mutation status assessed with the Myriad myChoice assay, including paired pre- and post-NAC analyses.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about HR status after NAC?",{"text":121,"@type":113},"Post-NAC HR assessment was unavailable in some patients due to insufficient or degraded tissue, but among evaluable paired cases tBRCA mutation status stayed unchanged, GIS decreased in HR-deficient tumors, and some patients converted from HRD to HRP after NAC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350378,1790254549,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Morimoto et al. Journal of Ovarian Research (2026) 19:204 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-026-02101-1](https://doi.org/10.1186/s13048-026-02101-1)  \nRESEARCH Open Access  \nDynamic changes in homologous   \nrecombination status before and after chemotherapy in advanced ovarian, fallopian tube, and primary peritoneal cancers  \nAkemi Morimoto1*, Takashi Matsumoto1, NorifumiTeramoto2, Sakiko Murakami1, Tomoka Usami 1, Junko Murai3 and Takashi Sugiyama1  \nAbstract  \nObjective Homologous recombination (HR) status plays a pivotal role in the management of advanced ovarian cancers, particularly in guiding the use of PARP inhibitors. In patients receiving neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS), tumor samples are available both before and after chemotherapy. This study evaluated the impact of NAC on HR status using paired pre-and post-NAC samples.  \nMethods Between 2020 and 2023, 128 patients with ovarian cancer were treated at our institution; 24 underwent NAC followed by IDS. Genomic instability scores (GIS) and tumor BRCA (tBRCA) mutation status were assessed using the Myriad myChoice® assay. Paired analyses included cases with both pre-and post-NAC samples.  \nResults Post-NAC HR assessment was unavailable in 8 of 24 patients (33%) due to insufficient or degraded tumor tissue. Paired HR status evaluation was therefore feasible in 15 patients. Among these paired evaluable cases, tBRCA mutation status remained unchanged. GIS scores significantly decreased in HR-deficient (HRD) tumors, whereas no significant change was observed in HR-proficient (HRP) tumors. The median ΔGIS was − 6, indicating a reduction after NAC. Two patients converted from HRD to HRP status after NAC, crossing the HRD threshold of 42.  \nConclusions Our findings suggest that NAC may reduce GIS and alter HR status in HRD tumors. Limited tissue availability after NAC poses a practical challenge for HR assessment, and HRD-to-HRP conversion may affect eligibility for HR-targeted therapies. These findings support performing HRD testing prior to chemotherapy whenever feasible. Keywords Homologous recombination deficiency (HRD), Ovarian cancer, Neoadjuvant chemotherapy, Interval debulking surgery, Genomic instability score (GIS)  \n*Correspondence:  \nAkemi Morimoto  \n[morimoto.akemi.ag@ehime-u.ac.jp](morimoto.akemi.ag@ehime-u.ac.jp)  \n1Department of Obstetrics and Gynecology, Ehime University, 454 Shitsukawa, Toon city, Ehime 791-0295, Japan  \n2Department of Pathology, Shikoku Cancer Center, KO160 MinamiUmemoto, Matsuyama city, Ehime 791-0245, Japan 3Proteo-Science Center, Ehime University, 454 Shitsukawa, Toon city, Ehime 791-0295, Japan  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nMorimoto et al. Journal of Ovarian Research (2026) 19:204  \nBackground  \nOvarian, fallopian tube, and primary peritoneal cancers (collectively refer","cbCairmsveYX7l1H","https://ap.wps.com/l/cbCairmsveYX7l1H","pdf",1298730,"English","# Abstract\n## Objective\n## Methods\n## Results\n## Conclusions\n# Background","[{\"question\":\"What was the primary objective of the study?\",\"answer\":\"To evaluate the impact of neoadjuvant chemotherapy (NAC) on homologous recombination (HR) status using paired tumor samples collected before and after NAC.\"},{\"question\":\"How were HR status and genomic changes measured?\",\"answer\":\"The study used genomic instability scores (GIS) and tumor BRCA (tBRCA) mutation status assessed with the Myriad myChoice assay, including paired pre- and post-NAC analyses.\"},{\"question\":\"What did the study find about HR status after NAC?\",\"answer\":\"Post-NAC HR assessment was unavailable in some patients due to insufficient or degraded tissue, but among evaluable paired cases tBRCA mutation status stayed unchanged, GIS decreased in HR-deficient tumors, and some patients converted from HRD to HRP after NAC.\"}]","Dynamic changes in homologous recombination status before and after chemotherapy in advanced ovarian, fallopian tube, and primary peritoneal cancers | PDF",1790088781,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8fe12de84ef44712f74a33135848790.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/283443b652985fc05b52cb62c3227290.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8103f9c9be8cbdadc92eeaa9efa11edd.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30e76b2b5d83e5b8e3b6ee15d850ee33.webp",980,1306]